193 related articles for article (PubMed ID: 33905571)
1. Clinicopathological factors and tumor microenvironment markers predicting watch-and-wait discontinuation in 82 patients with follicular lymphoma.
Yuda S; Miyagi Maeshima A; Taniguchi H; Ito Y; Hatta S; Suzuki T; Makita S; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Izutsu K
Eur J Haematol; 2021 Jul; 107(1):157-165. PubMed ID: 33905571
[TBL] [Abstract][Full Text] [Related]
2. The Adverse Consequences of Initial Watchful Waiting for Patients With Follicular Lymphoma.
Davies GA; Ghosh S; Oh DH; Manna M; Peters AC; Stewart CA; Stewart DA
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):829-835. PubMed ID: 30243571
[TBL] [Abstract][Full Text] [Related]
3. Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era.
Yuda S; Maruyama D; Maeshima AM; Makita S; Kitahara H; Miyamoto KI; Fukuhara S; Munakata W; Suzuki T; Kobayashi Y; Tajima K; Taniguchi H; Tobinai K
Ann Hematol; 2016 Dec; 95(12):2017-2022. PubMed ID: 27666284
[TBL] [Abstract][Full Text] [Related]
4. The role of "watch and wait" in intestinal follicular lymphoma in rituximab era.
Tari A; Asaoku H; Takata K; Fujimori S; Tanaka S; Fujihara M; Koga T; Yoshino T
Scand J Gastroenterol; 2016 Mar; 51(3):321-8. PubMed ID: 26382560
[TBL] [Abstract][Full Text] [Related]
5. The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.
Blaker YN; Spetalen S; Brodtkorb M; Lingjaerde OC; Beiske K; Østenstad B; Sander B; Wahlin BE; Melen CM; Myklebust JH; Holte H; Delabie J; Smeland EB
Br J Haematol; 2016 Oct; 175(1):102-14. PubMed ID: 27341313
[TBL] [Abstract][Full Text] [Related]
6. The outcome of watchful waiting in patients with previously treated follicular lymphoma.
Fujino T; Maruyama D; Maeshima AM; Saito Y; Ida H; Hosoba R; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Kuroda J; Izutsu K
Cancer Med; 2022 May; 11(10):2106-2116. PubMed ID: 35129305
[TBL] [Abstract][Full Text] [Related]
7. Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis.
Prica A; Chan K; Cheung M
Cancer; 2015 Aug; 121(15):2637-45. PubMed ID: 25877511
[TBL] [Abstract][Full Text] [Related]
8. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database.
Solal-Céligny P; Bellei M; Marcheselli L; Pesce EA; Pileri S; McLaughlin P; Luminari S; Pro B; Montoto S; Ferreri AJ; Deconinck E; Milpied N; Gordon LI; Federico M
J Clin Oncol; 2012 Nov; 30(31):3848-53. PubMed ID: 23008294
[TBL] [Abstract][Full Text] [Related]
9. A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait.
El-Galaly TC; Bilgrau AE; de Nully Brown P; Mylam KJ; Ahmad SA; Pedersen LM; Gang AO; Bentzen HH; Juul MB; Bergmann OJ; Pedersen RS; Nielsen BJ; Johnsen HE; Dybkaer K; Bøgsted M; Hutchings M
Br J Haematol; 2015 May; 169(3):435-44. PubMed ID: 25709094
[TBL] [Abstract][Full Text] [Related]
10. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
11. Is watch and wait still acceptable for patients with low-grade follicular lymphoma?
Armitage JO; Longo DL
Blood; 2016 Jun; 127(23):2804-8. PubMed ID: 26994147
[TBL] [Abstract][Full Text] [Related]
12. High TNFRSF14 and low BTLA are associated with poor prognosis in Follicular Lymphoma and in Diffuse Large B-cell Lymphoma transformation.
Carreras J; Lopez-Guillermo A; Kikuti YY; Itoh J; Masashi M; Ikoma H; Tomita S; Hiraiwa S; Hamoudi R; Rosenwald A; Leich E; Martinez A; Roncador G; Villamor N; Colomo L; Perez P; Tsuji NM; Campo E; Nakamura N
J Clin Exp Hematop; 2019; 59(1):1-16. PubMed ID: 30918139
[TBL] [Abstract][Full Text] [Related]
13. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.
Federico M; Bellei M; Marcheselli L; Luminari S; Lopez-Guillermo A; Vitolo U; Pro B; Pileri S; Pulsoni A; Soubeyran P; Cortelazzo S; Martinelli G; Martelli M; Rigacci L; Arcaini L; Di Raimondo F; Merli F; Sabattini E; McLaughlin P; Solal-Céligny P
J Clin Oncol; 2009 Sep; 27(27):4555-62. PubMed ID: 19652063
[TBL] [Abstract][Full Text] [Related]
14. PD1 distribution pattern, regardless of the cell origin, is an independent microenvironmental prognostic factor for progression-free survival in follicular lymphoma.
Szumera-Ciećkiewicz A; Poleszczuk J; Kuczkiewicz-Siemion O; Paszkiewicz-Kozik E; Rymkiewicz G; Sokół K; Borysiuk A; Kotarska M; Kawecka M; Owczarek D; Pytlak B; Walewski J; Prochorec-Sobieszek M
Pathol Res Pract; 2020 Oct; 216(10):153096. PubMed ID: 32853965
[TBL] [Abstract][Full Text] [Related]
15. Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy.
Maeng CH; Ahn SW; Ryu SY; Han S; Ko YH; Ji JH; Kim WS; Kim SJ
Korean J Intern Med; 2016 May; 31(3):560-9. PubMed ID: 26898595
[TBL] [Abstract][Full Text] [Related]
16. The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.
Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Hamouzova M; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
Ann Hematol; 2018 Apr; 97(4):669-678. PubMed ID: 29318369
[TBL] [Abstract][Full Text] [Related]
17. Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life.
Sortais C; Lok A; Tessoulin B; Gastinne T; Mahé B; Dubruille V; Blin N; Touzeau C; Moreau A; Bossard C; Peterlin P; Garnier A; Guillaume T; Le Bourgeois A; Chevallier P; Moreau P; Leux C; Le Gouill S
Ann Hematol; 2020 Jul; 99(7):1595-1604. PubMed ID: 32417940
[TBL] [Abstract][Full Text] [Related]
18. Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma.
Mondello P; Fama A; Larson MC; Feldman AL; Villasboas JC; Yang ZZ; Galkin I; Svelolkin V; Postovalova E; Bagaev A; Ovcharov P; Varlamova A; Huet S; Tesson B; McGrath KR; Slager S; Link BK; Syrbu S; Novak AJ; Habermann TM; Witzig TE; Nowakowski GS; Salles G; Cerhan JR; Ansell SM
Blood Cancer J; 2021 Jul; 11(7):130. PubMed ID: 34267181
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of histologic grade and Ki-67 proliferation index in follicular lymphoma.
Xue T; Yu BH; Yan WH; Jiang XN; Tian T; Zhou XY; Li XQ
Hematol Oncol; 2020 Dec; 38(5):665-672. PubMed ID: 32627854
[TBL] [Abstract][Full Text] [Related]
20. Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era.
Arushi Khurana ; Mwangi R; Ansell SM; Habermann TM; Cerhan JR; Strouse C; Link BK; Wang Y; King RL; Macon WR; Villasboas JC; Witzig TE; Maurer MJ; Nowakowski GS
Blood Cancer J; 2021 Jul; 11(7):133. PubMed ID: 34274939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
